Charlie Sheppard

Arjuna Therapeutics is a Spanish biotechnology company that specializes in developing a new class of small molecules called therapeutic molecular clusters (TMCs) for the treatment of cancer. Arjuna Therapeutics is based in A Coruña, Spain. TMCs are biomarker-driven and selectively kill cancer cells that exhibit high levels of ROS. The company believes that their approach to treating life-threatening diseases without effective treatment options will accelerate FDA approval. The company was founded by Fernando Dominguez and Arturo López Quintela, and the CEO is Ross Breckenridge.

Arjuna Therapeutics is a Spanish biotechnology company that specializes in developing a new class of small molecules called therapeutic molecular clusters (TMCs) for the treatment of cancer. Arjuna Therapeutics is based in A Coruña, Spain. TMCs are biomarker-driven and selectively kill cancer cells that exhibit high levels of ROS. The company believes that their approach to treating life-threatening diseases without effective treatment options will accelerate FDA approval. The company was founded by Fernando Dominguez and Arturo López Quintela, and the CEO is Ross Breckenridge.

Arjuna Therapeutics is a Spanish biotechnology company that specializes in developing a new class of small molecules called therapeutic molecular clusters (TMCs) for the treatment of cancer. Arjuna Therapeutics is based in A Coruña, Spain. TMCs are biomarker-driven and selectively kill cancer cells that exhibit high levels of ROS. The company believes that their approach to treating life-threatening diseases without effective treatment options will accelerate FDA approval. The company was founded by Fernando Dominguez and Arturo López Quintela, and the CEO is Ross Breckenridge.

Arjuna Therapeutics is a Spanish biotechnology company that specializes in developing a new class of small molecules called therapeutic molecular clusters (TMCs) for the treatment of cancer. Arjuna Therapeutics is based in A Coruña, Spain. TMCs are biomarker-driven and selectively kill cancer cells that exhibit high levels of ROS. The company believes that their approach to treating life-threatening diseases without effective treatment options will accelerate FDA approval. The company was founded by Fernando Dominguez and Arturo López Quintela, and the CEO is Ross Breckenridge.

Arjuna Therapeutics is a Spanish biotechnology company that specializes in developing a new class of small molecules called therapeutic molecular clusters (TMCs) for the treatment of cancer. Arjuna Therapeutics is based in A Coruña, Spain. TMCs are biomarker-driven and selectively kill cancer cells that exhibit high levels of ROS. The company believes that their approach to treating life-threatening diseases without effective treatment options will accelerate FDA approval. The company was founded by Fernando Dominguez and Arturo López Quintela, and the CEO is Ross Breckenridge.